4D Molecular Therapeutics (FDMT) Revenue (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Revenue of $3.0 million for Q1 2026, up 21664.29% year-over-year from N/an in Q1 2025, and down 96.42% on a QoQ basis from $85.1 million in Q4 2025.
4D Molecular Therapeutics (FDMT) has 7 years of Revenue data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Revenue rose 21664.29% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.2 million (up 383560.87% YoY) and the FY2025 annual result came in at $85.2 million, up 230194.59% from the prior year.
- Revenue declined to $3.0 million in Q1 2026 per FDMT's latest filing, from $85.1 million in the prior quarter.
- Across five years, Revenue topped out at $85.1 million in Q4 2025 and bottomed at -$19000.0 in Q4 2023.
- The 5-year median for Revenue is $162000.0 (2022), against an average of $6.6 million.
- The widest annual swing landed in 2023, when Revenue sank 101.52%; it then surged 8508900.0% in 2025.
- Tracing FDMT's Revenue over 5 years: stood at $1.2 million in 2022, then tumbled by 101.52% to -$19000.0 in 2023, then jumped by 105.26% to $1000.0 in 2024, then surged by 8508900.0% to $85.1 million in 2025, then slumped by 96.42% to $3.0 million in 2026.
- Per Business Quant, the three latest FDMT Revenue figures stand at $3.0 million (Q1 2026), $85.1 million (Q4 2025), and $90000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | 4D Molecular Therapeutics | 674.52 Mn | 674.52 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.05 Mn |
| Dec 31, 2025 | 85.09 Mn |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | -19,000.00 |
| Sep 30, 2023 | 20.20 Mn |
| Jun 30, 2023 | 239,000.00 |
| Mar 31, 2023 | 298,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 162,000.00 |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 92,000.00 |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 14.58 Mn |
| Mar 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | -977,000.00 |
| Sep 30, 2020 | 7.42 Mn |
| Jun 30, 2020 | 3.51 Mn |
| Mar 31, 2020 | 3.41 Mn |